Cancer immunotherapy: moving beyond current vaccines

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660

Toll-Like Receptors

Takeda, K., Kaisho, T., & Akira, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141126 · Cited by 6,143

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases

Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608

Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862

Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

The future of immune checkpoint therapy

Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878

Cancer immunotherapy comes of age

Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345

Regulatory T cells in cancer immunotherapy

Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860

Vaccine Adjuvants: Putting Innate Immunity to Work

Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924

Cancer immunoediting and resistance to T cell-based immunotherapy

O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759

Adoptive immunotherapy for cancer: harnessing the T cell response

Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688

A decade of immune-checkpoint inhibitors in cancer therapy

Robert, C. (2020) · Nature Communications · doi:10.1038/s41467-020-17670-y · Cited by 1,608

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Royal, R. E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U. S., Sherry, R. M., Topalian, S. L., Yang, J. C., Lowy, I., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181eec14c · Cited by 1,257

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000

Towards personalized, tumour-specific, therapeutic vaccines for cancer

Hu, Z., Ott, P. A., & Wu, C. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.131 · Cited by 1,067

An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma

Sahin, U., Oehm, P., Derhovanessian, E., Jabulowsky, R. A., Vormehr, M., Gold, M., Maurus, D., Schwarck-Kokarakis, D., Kuhn, A. N., Omokoko, T., et al. (2020) · Nature · doi:10.1038/s41586-020-2537-9 · Cited by 1,052

Microbiota: a key orchestrator of cancer therapy

Roy, S., & Trinchieri, G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.13 · Cited by 883

Combination strategies to maximize the benefits of cancer immunotherapy

Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01164-5 · Cited by 654

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

Senzer, N. N., Kaufman, H. L., Amatruda, T., Nemunaitis, M., Reid, T., Daniels, G., Gonzalez, R., Glaspy, J., Whitman, E., Harrington, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.3675 · Cited by 616

Developing a pro-regenerative biomaterial scaffold microenvironment requires T helper 2 cells

Sadtler, K., Estrellas, K., Allen, B. W., Wolf, M. T., Fan, H., Tam, A. J., Patel, C. H., Luber, B. S., Wang, H., Wagner, K. R., et al. (2016) · Science · doi:10.1126/science.aad9272 · Cited by 605

Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations

Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601

Cancer Immunotherapy Comes of Age

Topalian, S. L., Weiner, G. J., & Pardoll, D. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0899 · Cited by 586

Improving immune–vascular crosstalk for cancer immunotherapy

Huang, Y., Kim, B. Y. S., Chan, C. K., Hahn, S. M., Weissman, I. L., & Jiang, W. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.145 · Cited by 563

A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy

Xu, J., Lv, J., Zhuang, Q., Yang, Z., Cao, Z., Xu, L., Pei, P., Wang, C., Wu, H., Dong, Z., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-00781-4 · Cited by 561

CD8 + T‐cell memory in tumor immunology and immunotherapy

Klebanoff, C. A., Gattinoni, L., & Restifo, N. P. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00391.x · Cited by 511

Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma

Eyles, J., Puaux, A.-L., Wang, X., Toh, B., Prakash, C., Hong, M., Tan, T. G., Zheng, L., Ong, L. C., Jin, Y., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42002 · Cited by 506

Interleukin 12: still a promising candidate for tumor immunotherapy?

Lasek, W., Zagożdżon, R., & Jakobisiak, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1523-1 · Cited by 495

Analyses of repeated failures in cancer therapy for solid tumors: Poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs

Maeda, H., & Khatami, M. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0185-6 · Cited by 491

Nanoparticle-Based Immunotherapy for Cancer

Shao, K., Singha, S., Clemente-Casares, X., Tsai, S., Yang, Y., & Santamaria, P. (2015) · ACS Nano · doi:10.1021/nn5062029 · Cited by 470

Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors

Leko, V., & Rosenberg, S. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.013 · Cited by 449

'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations

Tran, E., Robbins, P. F., & Rosenberg, S. A. (2017) · Nature Immunology · doi:10.1038/ni.3682 · Cited by 443

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines

Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449

Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer

Antonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2013 · Cited by 444

IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells

Rosenberg, S. A., Sportès, C., Ahmadzadeh, M., Fry, T. J., Ngo, L. T., Schwarz, S. L., Stetler-Stevenson, M., Morton, K. E., Mavroukakis, S. A., Morre, M., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000210386.55951.c2 · Cited by 443

Emerging nanomedicine approaches fighting tumor metastasis: animal models, metastasis-targeted drug delivery, phototherapy, and immunotherapy

Liang, C., Xu, L., Song, G., & Liu, Z. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00458j · Cited by 435

mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer

Cafri, G., Gartner, J. J., Zaks, T., Hopson, K., Levin, N., Paria, B. C., Parkhurst, M. R., Yossef, R., Lowery, F. J., Jafferji, M. S., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134915 · Cited by 427

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer

Kirn, D. H., & Thorne, S. H. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2545 · Cited by 402

Biomaterials and emerging anticancer therapeutics: engineering the microenvironment

Gu, L., & Mooney, D. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.3 · Cited by 407

Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination

Van Tendeloo, V. F., Van de Velde, A., Van Driessche, A., Cools, N., Anguille, S., Ladell, K., Gostick, E., Vermeulen, K., Pieters, K., Nijs, G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008051107 · Cited by 377

TLR agonists: our best frenemy in cancer immunotherapy

Kaczanowska, S., Joseph, A. M., & Davila, E. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1012501 · Cited by 339

Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy

Ni, K., Lan, G., Chan, C., Quigley, B., Lu, K., Aung, T., Guo, N., La Riviere, P., Weichselbaum, R. R., & Lin, W. (2018) · Nature Communications · doi:10.1038/s41467-018-04703-w · Cited by 336

Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK–modified donor T cells after allogeneic hematopoietic cell transplantation

Berger, C., Flowers, M. E., Warren, E. H., & Riddell, S. R. (2006) · Blood · doi:10.1182/blood-2005-08-3503 · Cited by 334

A Novel Small Molecule Inhibitor of Signal Transducers and Activators of Transcription 3 Reverses Immune Tolerance in Malignant Glioma Patients

Hussain, S. F., Kong, L.-Y., Jordan, J., Conrad, C., Madden, T., Fokt, I., Priebe, W., & Heimberger, A. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1243 · Cited by 314

Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia

Rajasagi, M., Shukla, S. A., Fritsch, E. F., Keskin, D. B., DeLuca, D., Carmona, E., Zhang, W., Sougnez, C., Cibulskis, K., Sidney, J., et al. (2014) · Blood · doi:10.1182/blood-2014-04-567933 · Cited by 309

Immunomodulatory effects of cyclophosphamide and implementations for vaccine design

Sistigu, A., Viaud, S., Chaput, N., Bracci, L., Proietti, E., & Zitvogel, L. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0245-0 · Cited by 305

TNFR1 Signaling and IFN-γ Signaling Determine whether T Cells Induce Tumor Dormancy or Promote Multistage Carcinogenesis

Müller-Hermelink, N., Braumüller, H., Pichler, B., Wieder, T., Mailhammer, R., Schaak, K., Ghoreschi, K., Yazdi, A., Haubner, R., Sander, C. A., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.04.001 · Cited by 302

Tumor-infiltrating T lymphocytes: Friends or foes?

Yu, P., & Fu, Y.-X. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700389 · Cited by 299

CD8+ CTL Priming by Exact Peptide Epitopes in Incomplete Freund’s Adjuvant Induces a Vanishing CTL Response, whereas Long Peptides Induce Sustained CTL Reactivity

Bijker, M. S., van den Eeden, S. J. F., Franken, K. L., Melief, C. J. M., Offringa, R., & van der Burg, S. H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5033 · Cited by 279

Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy

Fan, Y., & Moon, J. (2015) · Vaccines · doi:10.3390/vaccines3030662 · Cited by 275

Therapeutic cancer vaccines: Are we there yet?

Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00979.x · Cited by 271

Blocking Hypoxia-Induced Autophagy in Tumors Restores Cytotoxic T-Cell Activity and Promotes Regression

Noman, M. Z., Janji, B., Kaminska, B., Van Moer, K., Pierson, S., Przanowski, P., Buart, S., Berchem, G., Romero, P., Mami-Chouaib, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1094 · Cited by 256

Engineering patient-specific cancer immunotherapies

Scheetz, L., Park, K. S., Li, Q., Lowenstein, P. R., Castro, M. G., Schwendeman, A., & Moon, J. J. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0436-x · Cited by 208

Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages

Stout, R. D., Watkins, S. K., & Suttles, J. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0209073 · Cited by 183

TLR8 signaling enhances tumor immunity by preventing tumor‐induced T‐cell senescence

Ye, J., Ma, C., Hsueh, E. C., Dou, J., Mo, W., Liu, S., Han, B., Huang, Y., Zhang, Y., Varvares, M. A., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201403918 · Cited by 161

Therapeutic cancer vaccines: From initial findings to prospects

Song, Q., Zhang, C.-D., & Wu, X.-H. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.01.011 · Cited by 106

Immunogenic Cell Death-Based Cancer Vaccines

Jin, M.-Z., & Wang, X.-P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.697964 · Cited by 99

Delivery Strategies for Immune Checkpoint Blockade

Chen, Q., Wang, C., Chen, G., Hu, Q., & Gu, Z. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800424 · Cited by 90

Immunotherapy for metastatic solid cancers

Turcotte, S., & Rosenberg, S. A. (2011) · Advances in Surgery · doi:10.1016/j.yasu.2011.04.003 · Cited by 81

Distinct Role for CD8 T Cells toward Cutaneous Tumors and Visceral Metastases

Lengagne, R., Graff-Dubois, S., Garcette, M., Renia, L., Kato, M., Guillet, J.-G., Engelhard, V. H., Avril, M.-F., Abastado, J.-P., & Prévost-Blondel, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.130 · Cited by 64

Immunological classification of tumor types and advances in precision combination immunotherapy

Ren, X., Guo, S., Guan, X., Kang, Y., Liu, J., & Yang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.790113 · Cited by 62

The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines

Wei, J., & Hui, A.-M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102405 · Cited by 57

Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Abdel-Rahman, O., Helbling, D., Schmidt, J., Petrausch, U., Giryes, A., Mehrabi, A., Schöb, O., Mannhart, M., & Oweira, H. (2017) · Clinical Oncology · doi:10.1016/j.clon.2016.11.007 · Cited by 55

Pegylated IL‐10 induces cancer immunity: The surprising role of IL‐10 as a potent inducer of IFN‐γ‐mediated CD8+ T cell cytotoxicity

Mumm, J. B., & Oft, M. (2013) · BioEssays · doi:10.1002/bies.201300004 · Cited by 53

A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors

Abdel-Rahman, O., & Fouad, M. (2016) · Immunotherapy · doi:10.2217/imt-2015-0020 · Cited by 46

Identification of a Promiscuous Epitope Peptide Derived From HSP70

Matsui, H., Hazama, S., Tamada, K., Udaka, K., Irie, A., Nishimura, Y., Miyakawa, T., Doi, S., Nakajima, M., Kanekiyo, S., et al. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000274 · Cited by 11